{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-096784","form_type":"8-K","ticker":"ELAB","cik":"0001840563","company_name":"PMGC Holdings Inc.","filed_at":"2026-09-02T21:04:24+00:00","discovered_at":"2026-09-02T21:06:00.462606+00:00","generated_at":"2026-09-02T21:06:09.026638+00:00","sec_items":["1.01","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMGC's NorthStrive expands AI drug program with Yuva, advances four compounds","bullets":["NorthStrive (PMGC) and Yuva execute First Amendment launching three-phase Expansion Program for four AI-discovered compounds.","Program builds on July 1, 2026 Phase III results (significant ANT1 increases); ~6 months to lead compound nomination.","Amendment grants right of first refusal for exclusive cardiometabolic license beyond Cardiac Diseases and Obesity.","Company increased authorized shares to 1.5B (1B common, 500M preferred) via Certificate of Amendment, 60.34% approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-096784","json":"https://secwatch.observer/filing/0001213900-26-096784.json","markdown":"https://secwatch.observer/filing/0001213900-26-096784.md","text":"https://secwatch.observer/filing/0001213900-26-096784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/0001213900-26-096784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/ea0304419-8k_pmgchold.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-02T21:06:09.026638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}